



20 August 2019

Company Announcements Office  
Australian Securities Exchange  
20 Bridge Street  
SYDNEY NSW 2000

**INFORMATION REQUIRED UNDER ASX LISTING RULE 3.10.5A**

Further to the Appendix 3B lodged on 20 August 2019 for the issue of 8,500,000 fully paid ordinary shares (**Placement**), Race Oncology Limited (ASX: RAC) provides the following information required under ASX Listing Rule 3.10.5A:

(a) The dilutive effect of the Placement on existing shareholders is as follows:

Number of Shares on issue prior to the Placement: 87,235,813

Placement issue under Listing Rule 7.1A (8,500,000 shares)	8.88%
Total dilution as a result of the Placement	8.88%

Number of Shares on issue following the Placement: 95,735,813

Details of the approximate percentage of the issued capital following the completion of the Placement held by pre-Placement shareholders and new shareholders are as follows:

Pre-Placement shareholders who did not participate in the Placement	91.04%
Pre-Placement shareholders who did participate in the Placement	8.96%
Participants in the Placement who were previously not shareholders	-

- (b) The Company issued the shares as a placement under Listing Rule 7.1A as it believed that this was the most efficient mechanism for raising funds at the time as it gives the Company certainty of raising the amount of capital.
- (c) No underwriting arrangements were in place for the Placement; and
- (d) There was no commission for the Placement.

Yours faithfully

**Peter Webse**  
Company Secretary